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1. Introduction  
According to the analysis of American Brain Tumor Association, the brain tumors are 
common with an incidence of 12.8 per 100,000 people. Glioma is the most common 
subgroup of brain tumors. It is a type of tumor that origins in the brain or spine. It is called a 
“glioma” because it arises from glial cells. According to the specific type of cells from which 
they originate, gliomas are categorized as glioblastoma (WHO grade IV), astrocytoma 
(WHO grades I–III), oligodendro -glioma (WHO grades II and III), and mixed glioma (WHO 
grades II and III) (McCarthy et al, 2011). It is reported that about 50% gliomas are 
glioblastomas, which are the most common and malignant phenotypic astrocytoma. They 
are most common in adults from ages 45-55, and affect more men than women. About 9% of 
brain tumors in childhood are glioblastomas. 
Gliomas are difficult to treat. Usually the prognosis for patients with high-grade gliomas 
(especially for glioblastomas) is very poor, which has a mean survival only from 10 to 12 
months (Reddy, et al, 2008). It is found that about 10,000 Americans are diagnosed annually 
with malignant gliomas, about half of these patients are survival 1 year after diagnosis, and 
25% after two years. The traditional approach to treat the glioma contains surgery, radidtion 
therapy and chemotherapy. Although with these treatments or combined approaches, the 
tumor will be suppressed at some means, the survival rate of the patients is still very low. 
Biomarker is a characteristic that is objectively measured as an indicator of normal biological 
processes, pathogenic processes or a pharmacological response to a therapeutic intervention 
(Atkinson et al., 2001; Marrer & Dieterle, 2007). And tumor/cancer biomarkers are involved 
in tumors which contain a wide variety of objects, including DNA, mRNA, secreted 
proteins, cell surface receptors, transcription factors, and metabolites, or processes such as 
apoptosis, angiogenesis or proliferation. The markers are produced either by the tumor itself 
or by other tissues or cells, in response to the presence of tumors or other associated 
irritation, like inflammation (Kulasingam & Diamandis, 2008). They can be found in the 
tumor tissues, tumor cell lines, secreted molecules and in the serum or other body fluid, and 
so on. The tumor/cancer biomarkers can help doctors to profile the cancer predisposition, 
state of cancerous development, early diagnosis, prognosis after tretment, and decide which 
drugs and at what does it might be most effective to the patients with tumors. They are also 
benefit to screen the targeted drug for the tumor treatment. 
Recent years, the tumor/cancer biomarkers have played important roles in the diagnosis, 
therapy and prognosis in tumors. For example, prostate-specific antigen (PSA), as a best-
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known cancer biomarker, is widely used to screen and diagnosis the prostate cancer (Barry, 
2001). In the United States (US), most prostate cancers are diagnosed through measurement 
of serum PSA. The serum PSA level correlates directly with prostate cancer risk and 
aggressiveness, as well as the outcomes after treatment. PSA testing is also useful in 
monitoring patients for tumor recurrence after treatment (Loeb & Catalona, 2007). The 
HER2/neu gene or protein has been found over-expression in 10% to 34% of breast cancers. It 
has been used as a diagnostic biomarker and also a treatment target in breast cancer. The 
clinical trial presented that systemic administration of anti-HER2 antibodies trastuzumab 
(Herceptin), alone and in combination with chemotherapy in patients with HER-2/neu 
overexpressing primary tumors, can increase the time to recurrence and overall response 
rates in metastatic breast cancer (Ross & Fletcher, 1998).  
Gliomas are difficult to remove due to several reasons. Firstly, some drugs can not get into 
gliomas directly because of the blood-brain barrier. Secondly, the gliomas can infiltrate the 
tissues around them, the traditional approaches, including surgery, radidtion therapy and 
chemo-therapy, can not get rid of them completely. Finally, gliomas may have more than 
one kind of tumor cells in them, so chemotherapy drug, which is only directed at one kind 
of tumor cells, can not kill the all tumor cells. Therefore, the investigations of glioma 
biomarkers for diagnosis, prognosis and therapy are an urgent mission for the scientist in 
future. 
2. The research progress of glioma biomarkers 
As far as we known, glioma biomarkers can be identified from the serum, cerebrospinal 
fluid, glioma cell lines or directly from glioma tissues. These biomarkers will help us to 
diagnose the gliomas in the earlier period, treat the glioma against the specific target and 
monitor the prognosis after treatment.  
2.1 Diagnostic biomarkers for glioma  
Currently, the examinations used in clinical diagnosis for glioma include computed 
tomography (CT) scan, magnetic resonance imaging (MRI) scan, angiogram, skull x-ray, 
spinal tap, myelogram and biopsy. But it is still difficult to diagnose in the earlier period of 
gliomas, until if we can find some specific biomarkers associated with the eraly 
development of gliomas, the diagnosis will be easy to decide. Diagnostic (or screening) 
biomarkers are used to detect and identify a given type of cancer in an individual. These 
markers are expected to have high specificity and sensitivity (Kulasingam & Diamandis, 
2008). 
(1) YKL-40 
YKL-40, also known as CHI3L1 or human cartilage glycoprotein-39, is a secreted 
glycoprotein. High levels of YKL-40 in serum have been implicated as a serum marker in a 
number of cancers including breast (Johansen et al, 1995; Jensen et al, 2003), colorectal 
(Cintin et al, 1999), and ovarian cancer (Dehn et al, 2003; Hogdall et al, 2003). Although the 
function of YKL-40 is not well elucidated, it is often over-expressed in epithelial cancers and 
gliomas. Previous studies suggested that YKL-40 was a marker associated with a poorer 
clinical outcome and a genetically defined histological subgroup of high-grade gliomas 
(Nutt et al, 2005).TheYKL-40 was also implicated as an important marker of radiation 
therapeutic response and overall survival in glioblastoma (Pelloski et al, 2005).  
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Later, Hormigo et al. found that except for YKL-40, matrix metalloproteinase-9 (MMP-9) 
protein was also highly differentially expressed in malignant gliomas (Hormigo et al, 2006). 
YKL-40 and MMP-9 were determined by ELISA using serum samples from patients with 
gliomas, and the results indicated that the values correlated with the patient’s radiographic 
status and survival. So , YKL-40 and MMP-9 may be used as a biomarker in glioma patients’ 
serum and help confirm the absence of active disease in glioblastoma multiforme.  
(2) GFAP 
Another protein, glial fibrillary acidic protein (GFAP), first reported by Eng et al. in 1971, is 
a member of the cytoskeletal protein family and is widely detected in astroglial cells and 
neural stem cells (Eng et al, 1971, 2000; Doetsch, 2003; Jung et al, 2007). It is also expressed in 
astrocytoma and glioblastoma multiforme (Jacque et al, 1978; Hamaya et al, 1985; Abaza et 
al, 1998). A serum marker for malignant gliomas may improve both differential diagnoses 
with different histological subtypes and clinical management of glioma tumor patients. Jung 
et al. investigated GFAP levels in the serum of glioblastoma multiforme patients and 
various control groups. Their studies showed that the serum GFAP levels of these patients 
were significantly higher than those of patients with WHO grade II or III astrocytomas or of 
patients with brain metastases. And the serum GFAP concentration was closely linked with 
the glioblastoma volume and tumor necrosis volume imaged from magnetic resonance 
imaging scans. Therefore, the serum GFAP may be used as a diagnostic biomarker for 
glioblastoma multiforme. But it is necessary to evaluate whether the serum GFAP could be 
used to monitor therapeutic effects or have a prognostic value in future studies (Jung et al, 
2007). Furthermore, it is reported that GFAP does not provide a better staining for 
distinguishing histologic subtypes of high-grade glioma by immunohistochemistry. 
Compared with GFAP, YKL-40 staining, is a stronger marker, provided a better class 
distinction. In addition, using a combination of YKL-40 and GFAP staining could afford 
even greater diagnostic accuracy (Nutt et al, 2005).  
(3) Other potential biomarkers  
Cerebrospinal fluid (CSF) was usually used to screen glioma biomarkers because of its 
closer relation with glioma and its relative ease of collection (Maurer et al, 2003). 
Furthermore, CSF has about 1000 proteins, which is 100~400 fold lower than in serum, and 
this will be facilitated to screen the specific protein biomarkers (Omenn, 2005). In the past 
decades, many markers have been found in CSF of glioma patients, such as S100, neuron-
specific enolase (NSE), recoverin (protein A) and vascular endothelial growth factor (VEGF) 
(Gronowitz et al, 1984; Cochran & Wen, 1985; Taomoto et al., 1987; Sampath et al., 2004; 
Khwaja et al, 2007). However, these biomarkers could not be widespread used due to the 
limitation of repetition in CSF examinations.  
Recently, new candidate biomarkers have been identified by proteomics analysis for CSF 
samples. For example, Khwaja et al. used two-dimensional gel electrophoresis (2-DE) and 
cleavable Isotope-Coded Affinity Tag (cICAT) to analyze CSF proteome to detect specific 
biomarkers in brain tumors with differing histologies and grades (Khwaja et al, 2007). 
Finally, 20 potential tumor-specific markers were specially identified in high-grade 
astrocytoma. These potential markers may also play important role in the development and 
malignant progression of human astrocytoma and will be the treatment targets in glioma. 
Furthermore, exosome is now becoming a hot spot to look for cancer biomarkers. Exosomes 
are 50-90 nm vesicles-like objects secreted by various mammalian cells. An exosome is 
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formed intracellularly when a segment of cell membrane spontaneously invaginates and is 
endocytosed (Keller et al, 2006). It is reported that dendritic cells and B cells could secrete 
exosomes, which indicated that exosomes may play a functional role in mediating adaptive 
immune responses to pathogens and tumors (Li et al, 2006). Exosomes can also be detected 
in urine and they might serve as a diagnosis and treatment response marker in prostate 
cancer (Pisitkun et al, 2004; Nilsson et al, 2009). Therefore, exosomes, which are released 
from tumors into the blood, can also be used for diagnosis. The released exosomes by 
glioblastoma tumor cells contain mRNA, microRNA and angiogenic proteins (Balaj et al, 
2011). Furthermore, the glioblastoma-derived exosomes serve as a vehicle to deliver genetic 
information and proteins in the tumor environment. Tumor mutations in glioma can be 
detected in exosomes from serum, which is also facilitating a blood-based biomarker 
detection for solid tumors (Skog et al, 2008). Thus, tumor-derived exosomes may be used as 
a diagnostic biomarker and aid in therapeutic decisions for glioma patients.  
  Although the histopathologic methods are often used to classify the pathologic grade of 
gliomas in clinical diagnosis, the results are usually subjective and less accurate. To 
overcome the limitations, cDNA microarray has been performed to screen diagnostic and 
prognostic markers for glioblastoma. The growth arrest and DNA-damage-inducible ǂ 
(GADD45ǂ ) and follistatin-like 1 (FSTL1) were over-expressed in most primary and 
secondary glioblastomas, whereas superoxide dismutase 2 and adipocyte enhancer binding 
protein 1 were up-regulated in the majority of primary glioblastomas (Reddy et al, 2008). All 
the results were validated by real-time reverse transcription quantitative PCR and 
immunohistochemical analysis. These findings suggested that GADD45ǂ and FSTLI are 
glioblastoma-specific whereas superoxide dismutase 2 and adipocyte enhancer binding 
protein1 are primary glioblastoma-specific diagnostic markers. It is interesting to found that 
the diffusion parameters could also be evaluated as early biomarkers of disease progression 
in glioblastoma multiforme (Khayal et al, 2010).  
2.2 Prognostic biomarkers for glioma  
Tumor prognostic biomarkers are used once the tumor status has been confirmed. These 
biomarkers are expected to predict the probable course of the tumors including its 
recurrence, and they therefore have important influences on the aggressiveness of therapy 
(Kulasingam & Diamandis, 2008). 
It is known that O(6)-methylguanine-DNA methyltransferase (MGMT) can recover the 
carcinogenic lesion in DNA induced by alkylating mutagens. What’s more, it has been 
showed that methylation of the MGMT’s promoter plays a significant role in carcinogenesis 
(Hegi et al, 2005). The hypermethylation in MGMT promoter has been detected in other 
various of human cancers, such as colon cancer, nonsmall-cell lung cancer, head and neck 
carcinoma, lymphomas, Leukemias, pancreatic carcinoma , melanoma, renal carcinoma and 
bladder carcinoma (Esteller et al, 1999). The hypermethylation frequency of MGMT 
promoter varies widely in different subtype glioma. It has ranged from 35% to 73% in 
glioblastoma, about 50%~84% in diffusely infiltrating anaplastic gliomas (World Health 
Organization grade III), as well as about 43%~93% in the WHO grade II counterparts 
(Deimling et al, 2011). Although the methylation of MGMT status appears to be a useful 
prognostic marker in the elderly patients with newly diagnosed glioblastoma (Gerstner et al, 
2009). In fact, MGMT immunohistochemistry analysis had some lacks for routine diagnostic 
purposes due to the observer variability as well as lack of association with the MGMT 
promoter methylation status (Preusser et al, 2008). 
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As is known to all, the ras GTPase-activating-like protein IQGAP1 functions as a scaffold 
protein which is involved in cellular motility and morphogenesis (Mateer et al, 2003). It is 
participated in many signaling pathways to regulate cell adhesion, polarization and 
migration. For example, IQGAP1 was played as a VEGFR2-associated scaffold protein to 
organize ROS-dependent VEGF signaling, which could promote the migration and 
proliferation of endothelial cell to repair the injured vessels (Yamaoka-Tojo et al, 2004). It is 
also identified as a core component of neuronal motility signal transduction and it is 
involved in epithelial carcinogenesis and metastasis (Briggs & Sacks, 2003; Kholmanskikh et 
al, 2006; Balenci et al, 2006). But, one recent study found that IQGAP1 may be used as a 
marker to discriminate the human glioblastoma from oligodendroglioma (Balenci et al, 
2006) 
Another known protein，the insulin-like growth factor-binding protein 2 (IGFBP2) is 
usually detected in many human tumors, including malignancies of the lung, colon, adrenal 
glands, ovary, prostate, CNS and lymphoid tumors (Dunlap et al, 2007). Its overexpression 
is often linked with an increasingly malignant status of the tumor, indicating a potential 
oncogene function of IGFBP-2 in tumorigenesis (Hoeflich et al, 2001). IGFBP2 was also 
identified as a specific marker for central nervous system (CNS) tumors and might serve as 
a marker of tumor differentiation (Muller et al, 1994; Akmal et al, 1995). Furthermore, the 
plasma IGFBP2 levels are obviously higher in high-grade glioma patients than in low-grade 
glioma patients and healthy subjects. All these data indicate the plasma IGFBP2 has a 
biomarker’s role in glioma (Lin et al, 2009).  
The coexpression of IQGAP1 and IGFBP2 is strongly associated with poor prognosis in 
astrocytoma and oligodendroglioma. These findings might complement the WHO 
classification system to permit more precise classification for glioma subtypes. Besides, in 
glioblastoma patients who had shown long-term survival of >3 years after initial diagnosis, 
the expression of IQGAP1 and IGFBP2 were not be detected. Thus, the absence of IQGAP1 
and IGFBP2 may be a good prognostic marker in glioblastoma patients. However, the 
relationship between IQGAP1 and IGFBP2 and their roles in glioma biology are still need to 
be elucidated in future (McDonald et al, 2007).  
Matrix-assisted laser desorption ionization- mass spectrometry (MALDI-MS) is a high-
throughput and accurate tool in proteomics research. It has been used to profile the glioma-
specific protein patterns which can provide clinically relevant information on tumor 
malignancy. The glioma-specific protein patterns could accurately classify glioma subtypes 
and discriminate patient survival patterns. Still, there are several discriminatory proteins 
were identified, including calcyclin, dynein light chain 2 (DLD2), calpactin I light chain, 
astrocytic phosphoprotein (PEA-15), fatty acid-binding protein 5 (FABP5) and tubulin -
specific chaperone A. These proteins were reported to be involved in various aspects of 
tumorigenesis. These differential expression proteins in gliomas may provide as diagnostic 
and prognostic markers (Schwartz et al, 2005).  
Tumor is a disease coupled with multiple gene alterations. The gene expression pattern may 
predict the survival time in patients with high-grade gliomas independently of other factors 
(Czernicki et al, 2007). Proteins are the true executors that directly perform functions 
regulated by genes. Therefore, the protein changes would be more attractive in cancer 
biomarker discovery (Liang et al, 2011). Khalil used the two-dimensional difference gel 
electrophoresis (2D-DIGE) compared protein patterns between glioma tissues and non-
tumor brain tissues. About 20 unique differential proteins were identified, and these 
proteins with diagnostic or prognostic value are still needed to be validated in future 
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research (Khalil, 2007). In addition, the gelsolin protein is significantly lower expressed in 
the increscent glioma histopathologic grade. And in astrocytoma, the overall survival in the 
low-expression group was significantly poorer than in the high expression group. Therefore, 
gelsolin may be a prognostic marker for astrocytoma patients (Ohnishi et al, 2009). Besides, 
the B-chain of ǂ2 -heremans-schmid glycoprotein in serum can be used as a potential 
biomarker for glioma prognosis (Petrik et al, 2008).  
DNA microarray is usually used to measure gene expression levels, single nucleotide 
polymorphisms or genotype. It is one of the fastest-growing new technologies in cancer 
research. By DNA microarray, it was found that metalloproteinase-4 (TIMP-4) and its 
putative partner CD63 were coexpressed in glioblastomas and pilocytic astrocytomas. High 
TIMP-4 /CD63 co-expression level has been found to be an independent prognostic marker 
associated with progression and shorter survival in glioblastomas. On the contrary,the 
higher co-expression indicted adverse outcomes in diffuse astrocytoma and 
oligoastrocytoma patients (Rorive et al, 2010). Similarly, a high level of osteopontin protein 
in serum indicates a poor prognosis in glioblastoma patients, and it may be a poor 
prognostic biomarker in glioblastoma patients (Sreekanthreddy et al, 2010).  
Gene mutation is another factor in carcinogenesis. Recently, the isocitrate dehydrogenase 1 
(IDH1) was analyzed by direct sequencing in a series of 404 glioma patients with different 
grade. It is found that the mutation rates in the codon 132 of IDH1 were obviously decreased 
with increscent glioma grade, which indicated that the codon 132 mutations of IDH1 could 
be an important prognostic marker in grade 2 to 4 gliomas (Sanson et al, 2009). The codon 
132 mutation of IDH1was detected in more than 70% of WHO grade II - III astrocytomas , 
oligodendrogliomas, as well as in glioblastomas which are developed from those lower-
grade gliomas. Gliomas, without mutations in IDH1 codon 132, often had mutations in 
codon 172 of the IDH2 gene. The results showed that patients with such mutations in IDH 
usually had a better prognosis than those with wild-type IDH genes (Yan et al, 2009).  
2.3 Therapeutic targets for glioma  
Recent developments in the field of tumor biology have elucidated signalling pathways and 
genes involved in the development of gliomas, which represent new potential therapeutic 
targets, and many targeted therapies are currently being tested in clinical trials (Sanson, 
2008).  
(1) Receptor tyrosine kinases (RTKs)-mediated signaling 
The antiangiogenesis strategy has been widely used in molecularly targeted therapy for 
malignant glioma. Angiogenesis in tumors is caused by a number of factors involved in 
many signaling pathways, in which the VEGF-VEGFR2 is a major and more attractive 
pathway. Currently, many angiogenesis inhibitors or antibodies have been applied in 
clinical studies. These inhibitors or antibodies were usually design to anti-specific factors, 
including VEGF itself, VEGFR, and other upstream /downstream factors regulated the 
VEGF signaling pathway, such as Cox-2, HIF-1ǂ, and so on(Chi et al, 2009).  
Gliomas are highly heterogeneous in terms of biological alterations. Mutations in EGFR and 
genes for other receptor tyrosine kinases (RTKs), namely platelet-derived growth factor 
(PDGFR), HER2/neu and MET, lead to activation of downstream PI3K-AKT and ERK-MEK 
pathways in gliomas. Therefore, several antiangiogenic inhibitors, which downregulate 
EGFR-mediated signaling, have recently been developed and tested as therapeutic agents, 
including cediranib (Recentin, AstraZeneca), vatalanib (Novartis Pharmaceuticals, Basel, 
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Switzerland), sunitinib (Sutent, Pfizer), sorafenib (Nexavar, Bayer Pharmaceuticals, 
Leverkusen, Germany), vandetanib (Zactima, AstraZeneca) and VEGF trap (Aflibercept, 
Regeneron Pharmaceuticals, NY,USA) (Lukas et al,2009; Roesler et al, 2010). Besides small-
molecule inhibitors, therapies can be targeted to tumor cells (e.g., EGFR inhibitors) or tumor 
blood vessels with the monoclonal antibody against VEGF, bevacizumab (Avastin; 
Genentech, CA, USA).  
However, followed by the antiangiogenesis therapy at long time, the patients will have a 
high resistance to anti-VEGF therapies. Soda et al. investigated the resistance mechanism of 
anti-VEGF therapy to glioma in the transduction of p53+/− heterozygous mice containing 
oncogenes and in the GFAP-Cre recombinase (Cre) mice. It was found that mouse 
glioblastoma cells could be transdifferented into vascular endothelial cells (tumor -derived 
endothelial cells, TDECs) in the hypoxia situation, and this process was independent of 
VEGF. A further study has showed that the formation of TDECs are also presented in the 
xenograft model of human glioblastoma spheres directly from the patients with 
glioblastoma (Sodaa et al, 2011). These studies show that the TDECs may have an important 
role in the resistance to anti-VEGF therapy, and hence they could be a candidate target for 
glioblastoma therapy. But there are still many questions need to be answered. For example, 
what are the signaling molecules that participate in the production of TDECs? Is this 
mechanism of VEGF-A resistance uniform to all glioblastoma or are there alternate 
pathways used for different subsets of glioblastoma? (Sodaa et al, 2011; Hormigo et al, 2011).  
(2) PI3K/AKT/mTOR pathways 
PI3K pathways regulate several malignant phenotypes including antiapoptosis, cell growth, 
and proliferation. Activation of PI3K pathway is associated with poor prognosis in glioma 
patients (Sathornsumetee et al, 2007). Activated PI3K phosphorylates several downstream 
effectors including AKT. AKT is a serine/threonine kinase that regulates cell growth, 
proliferation, and apoptosis. The mTOR is a serine/threonine kinase downstream from AKT.  
Several mTOR inhibitors have been studied in the treatment of malignant glioma. These 
include sirolimus (Rapamune; Wyeth Pharmaceuticals,Madison, NJ) FDA-approved for the 
prophylaxis of solid organ transplant rejection, and temsirolimus (CCI-779, Torisel; Wyeth 
Pharmaceuticals) FDA-approved for use in renal cancer (Lukas et al, 2009). And everolimus 
(RAD001; Novartis Oncology, East Hanover, NJ) and deferolimus (AP23573; 
ARIAD/Merck), still experimental, have all been evaluated in clinical trials alone or in 
combination with other therapies in gliomas. Although data strongly support the view of 
the PI3K–AKT–mTOR pathway as an important target, current clinical results on the use of 
mTOR inhibitors remain disappointing. For example, the Phase II studies using 
temsirolimus as monotherapy found only limited activity in recurrent glioblastoma 
multiforme. Because pathways are complex interactive networks characterized by cross-talk 
and homeostatic feedback loops that can greatly influence response to therapy. 
(3) Histone deacetlyase (HDAC) 
Histone deacetylases (HDACs), regulating histone acetylation, are now considered to be a 
promising target for gliomas. The epigenetic therapies, particularly HDAC inhibitors 
(HDACis), have been proposed as potential novel drugs. Suberoylanilide hydroxamic acid 
(SAHA, vorinostat, Zolinza; Merck), FDA-approved for cutaneous T-celllymphoma, is being 
evaluated in clinical trials of multiple cancers, including malignant gliomas 
(Sathornsumetee et al, 2007; Roesler et al, 2010).  
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(4) Other targets and therapeutic approaches 
Advances in the understanding of cellular and molecular alterations in gliomas have led to 
the emergence of experimental molecularly targeted therapies. The targeted therapies for 
glioma include small molecules and antibodies targeted at growth factor pathways, 
intracellular signaling cascades and epigenetic molecular targets, as well as RNAi, gene 
therapy and neural stem cells as therapeutic tools (Roesler et al, 2010). 
The receptor protein tyrosine phosphatase ǃ (RPTPǃ) have a role to facilitate tumor cell 
adhesion and migration by interactions with extracellular matrix components and the 
growth factor pleiotrophin. Over-expression of RPTPǃ was found in several types of solid 
tumor, but with low expression in normal tissue (Foehr et al, 2006). It is reported that RPTPǃ 
was displayed strong staining in oligodendrogliomas, and may be a novel 
oligodendroglioma marker (Hӓgerstrand et al, 2008). Therefore, RPTPǃ may perform a role 
of potential therapy target in gliomas and other tumors. The monoclonal antibodies of 
RPTPǃ obtained from immunizing mice could kill glioma cells in vitro and significantly 
suppress the growth of human glioma tumors in a xenograft mouse model (Foehr et al, 
2006).  
The PBEF1 (Pre-B-cell colony enhancing factor 1) gene may be a potential malignant 
astrocytoma serum marker and prognostic indicator in glioblastoma (Reddy et al, 2008). 
PBEF1 gene encodes nicotinamide phosphoribosyltransferase (NMPRTase), which has an 
important role in the salvage pathway of NAD+ biosynthesis. The inhibitor of NMPRTase, 
such as FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors (Khan et al, 
2006). Therefore, the novel inhibitor of NMPRTase may be used as an anti-tumor drug in 
glioma therapy (Chandra et al, 2011).  
However, targeting a single component of cell signaling, or a single signaling pathway, is 
not likely to effectively reduce tumor growth in glioma patients. Preclinical studies should 
characterize the effects of multi-targeted inhibitors, combining several targeted inhibitors, 
and combining targeted therapies with cytotoxic chemotherapy. 
Tumor stem cells are a kind of specific tumor cells which have the stem cell like properties. 
It is reported that glioma stem cells display self-renewal and proliferation properties, 
unlimited life span, a high migration rate and resistance to chemotherapy, and they are 
capable of replenishing the whole tumor cell population (Singh et al, 2003; 2004). The glioma 
stem cells have been involved in many signaling pathways, including Notch, Hedgehog, 
Wnt, Myc, PI3K and MAPK cascades, and so on (Das et al, 2008; Li et al, 2009; Roesler et al, 
2010). According to the important roles of glioma stem cells, the drugs that directly and 
specifically kill the glioma stem cells will be more effective than other ways in glioma 
therapy. Some studies have proposed the possible strategies to target the glioma stem cells. 
One way is using differentiating agents (like bone morphogenetic proteins, BMPs)to induce 
the glioma stem cells into mature, astrocytic cells, and another way is regulating the 
expression of targeting genes involved in glioma stem cell proliferation (Piccirillo et al, 2006; 
Horvath et al, 2006). 
3. Discussion and outlook 
It is clear that more and more high-throughput, accurate technologies or strategies have 
been used in identification of glioma biomarkers (shown in Figure 1). These techniques 
include ELISA (Hormigo et al, 2006; Lin et al, 2009; Sreekanthreddy et al, 2010), 2-DE 
(Khwaja et al, 2007; Khalil, 2007; Ohnishi et al, 2009), DNA microarray (Reddy et al, 2008), 
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Fig. 1. Current different techniques are used in the glioma biomarker discovery. 
a. CSF: Cerebrospinal fluid; IHC: immunohistochemistry; ELISA: enzyme linked 
immunosorbent assay; 2-DE: two-dimensional electrophoresis; MS: mass spectrometry.  
b. The quantitative approaches here contain the isotope-coded affinity tag (ICAT), stable 
isotope labeling with amino acids in cell culture (SILAC), isobaric tagging for relative and 
absolute quantitation (iTRAQ). 
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MALDI-MS or SELDI-TOF -MS (Petrik et al, 2008; Schwartz et al, 2005),direct sequencing 
(Sanson et al, 2009), ICAT (Khwaja et al, 2007), and transgenic mouse etc (Sodaa et al, 2011). 
A number of quantitative approaches summarized in Figure 1, with different technical 
advantages and challenges, have been developed for glioma biomarker discovery. However, 
many complementary technologies are being developed and either alone or in combination 
will undoubtedly allow their potential in biomedical research and translation into clinical 
practice. 
Recently, we have investigated the protein prfiling in low-grade gliomas by a quantative 
SILAC (stable isotope labeling with amino acids in cell culture) –based protemoics strategy 
in order to screen novel glioma-specific proteins (Liang et al, 2009a; Shen et al, 2010). 
Besides, the quantative protemoics strategy also contains the isotope-coded affinity tag 
(ICAT), isobaric tagging for relative and absolute quantitation (iTRAQ), and so on. With 
these high-throughput and sensitive approaches, more specific glioma biomarkers will be 
identified (Liang et al, 2009b).  
In conclusion, the glioma biomarkers primarily can be classed into three kinds, including 
diagnostic biomarkers, prognostic markers and therapeutic targets. In fact, only few 
biomarkers could be used in clinical applications, such as o (6)-methylguanine-DNA 
methyltransferase (MGMT) (Gerstner et al, 2009; Deimling et al, 2011), VEGF and VEGFR 
(Chi et al, 2009), and so on (shown in Table 1). The other potential biomarkers for glioma are  
 
Target gene/protein 
Clinical 
Application 
Phase Drug 
MGMT (Methylguanine methyl 
transferase) 
diagnosis and 
prognosis 
--- --- 
EGFR (Epidermal growth factor 
receptor) 
therapy Phase II MAb-425 
  --- Erlotinib 
  Phase III Nimotuzimab 
  Phase I/II Gefitinib 
  Phase I/II Cetuximab 
VEGF (Vascular endothelial 
growth factor) 
therapy Phase II 
Bevacizumab / 
Irinotecan 
VEGFR (Vascular endothelial 
growth factor receptor) 
therapy Phase I/II Vatalanib 
PDGFR (Platelet-derived growth 
factor receptor) 
therapy Phase II 
Crenolanib (CP-
868,596) 
  Phase II Nilotinib 
  Phase I/II Imatinib 
mTOR (mammalian target of 
rapamycin) 
therapy Phase III Everolimus   
  Phase II Temsirolimus 
  Phase I Sirolimus+Gefitinib 
HDAC (histone deacetlyase) therapy Phase I/II SAHA 
COX-2 (cyclooxegenase-2) therapy Phase I/II Celecoxib 
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Target gene/ protein 
(or other object) 
Candidate 
Applications
Localization (a) References 
YKL-40 
Diagnosis & 
prognosis 
Serum or tumor 
tissues 
Nutt et al, 2005; Hormigo et 
al, 2006 
MMP-9 
Diagnosis & 
prognosis 
Serum Hormigo et al, 2006 
GFAP 
Diagnosis & 
prognosis 
Serum or tumor 
tissues 
Nutt et al, 2005; Jung et al, 
2007 
Exosomes Diagnosis 
Serum or tumor 
tissues 
Skog et al, 2008; Balaj et al, 
2011 
GADD45┙ and FSTL1 Diagnosis Tumor tissues Reddy et al, 2008 
Diffusion parameters Diagnosis Tumor tissues Khayal et al, 2010 
MGMT 
Diagnosis & 
prognosis 
Tumor tissues Gerstner et al, 2009 
IQGAP1 
Diagnosis & 
prognosis 
Tumor tissues 
Balenci et al, 2006; McDonald 
et al, 2007 
IGFBP2 
Diagnosis & 
prognosis 
Serum or tumor 
tissues 
McDonald et al, 2007; Lin et 
al, 2009 
    
*Calcyclin,*DLC2 , 
*CalpactinI light chain, 
*PEA-15, *FABP5, 
*Tubulin-specific 
chaperone A 
Diagnosis & 
prognosis 
Tumor tissues # Schwartz et al, 2005 (b) 
AHSG Prognosis Serum Petrik et al, 2008 
Gelsolin Prognosis Tumor tissues Ohnishi et al, 2009 
IDH1/IDH2 mutation Prognosis Tumor tissues 
Sanson et al, 2009, Yan et al, 
2009 
TIMP-4/CD63 Prognosis Tumor tissues Rorive et al, 2010 
Osteopontin protein Prognosis Serum Sreekanthreddy et al, 2010 
FoxM1 Therapy Tumor tissues Liu et al, 2006 
RPTP┚ Diagnosis & 
therapy 
Tumor tissues 
Foehr et al, 2006, 
Hӓgerstrand et al, 2008 
PBEF1(NMPRTase) 
Prognosis & 
therapy 
Serum or tumor 
tissues 
Reddy et al, 2008, Chandra et 
al, 201 
Glioma stem cells Therapy Tumor tissues 
Piccirillo et al, 2006; Horvath 
et al, 2006 
TDECs (tumor -derived  
endothelial cells) 
Therapy Tumor tissues 
Sodaa et al, 2011; Hormigo et 
al, 2011 
 
a. The sample pool where the biomarkers were identified. 
b. The biomarkers with * tag were identified in the same study with # tag. 
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promised to need a further validation and confirmation (shown in Table 2). There have 
some limitations for application of glioma biomarkers in the clinical trial. Firstly, the 
specification of biomarkers is always not certainly. Because of the biomarkers are usually 
detected in both normal and tumor samples, and other diseases can also cause the changes 
of biomarkers. And then, the investigation strategy of biomarkers are significantly various. 
Even if used the same type samples, the results will be remarkably difference. Finally, the 
patients with tumors are usually difference from each other, also called the individual 
difference. Besides, the overall samples used in biomarker identification are still limited due 
to various gaps. In spite of this, the studies of glioma biomarker identification still have a 
bright future by the continuous efforts of biologists. 
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